Skip to main content

Advertisement

Table 1 Demographics of RA patients included in BIOREG at baseline (if not otherwise indicated, median (25th and 75th percentile))

From: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria

  All pts EST New
n 970 284 62
Age (years) 58.0 (50.0; 68.0) 59.0 (48.0, 67.0) 58.0 (47.0, 70.0)
Disease duration (years) 8.0 (4.0, 14.0) 9.00 (5.0, 14.0) 4.00 (1.00, 9.00)
Gender % female 77.3 78.4 77.4
RF pos % 69.3 (n = 894) 68.0 (n = 264) 54.8 (n = 59)
ACPA pos % 47.6 (n = 633) 50.0 (n = 193) 37.1 (n = 46)
Duration of bDMARD treatment prior inclusion (years) 1.99 (0.22, 5.18) 3.22 (1.53, 6.02) na
DAS28 3.26 (2.24, 4.20) 2.67 (1.99, 3.70) 4.46 (3.77, 5.35)
RADAI-5 3.2 (1.6, 4.8) 2.6 (1.2, 4.4) 4.4 (3.2, 6.2)
HAQ-DI 0.75 (0.25, 1.25) 0.63 (0.13, 1.19) 1.00 (0.63, 1.38)
GC % 35.9 25.0 66.1
csDMARD % 64.6 56.0 83.9
  1. Abbreviations: ACPA Anti Citrullinated Peptide Antibodies, bDMARD biological DMARD, csDMARD concomitant conventional synthetic DMARD, DAS28 Disease Activity Score using ESR out of 28 joints, ESR erythrocyte sedimentation rate, EST pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, GC concomitant glucocorticoid treatment, HAQ-DI Health Assessment Questionnaire Disability Index, N number of patients, NA not applicable, NEW pts included in BIOREG with start of biologic treatment ± 30 days of whom a full data set as described is viable, PTS patients, RA rheumatoid arthritis, RADAI-5 Rheumatoid Arthritis Disease Activity Index-5, RF Rheumatoid Factor